Takeda Completes Acquisition of IDM Pharma, Inc.

Acquisition Adds MEPACT to Takeda`s Oncology Portfolio
NEW YORK--(Business Wire)--
Takeda Pharmaceutical Company Limited ("Takeda", TSE: 4502) today announced the
completion of its acquisition of IDM Pharma, Inc. ("IDM", NASDAQ: IDMI) for
US$2.64 per share in cash, through a short-form merger of Jade Subsidiary
Corporation ("Jade"), a wholly owned subsidiary of Takeda America Holdings,
Inc., which is a wholly owned subsidiary of Takeda, into IDM. With the
consummation of the merger, IDM has become a wholly owned subsidiary of Takeda
America Holdings, Inc. This acquisition adds MEPACT (mifamurtide), a novel
therapy indicated for the treatment of osteosarcoma, to the Takeda oncology
portfolio in Europe.

"With the closing of this acquisition, we look forward to launching MEPACT in
Europe. This novel therapy, the first treatment approved for osteosarcoma in
more than 20 years, has the potential to benefit patients in an area where new
treatments are urgently needed," said Erich Brunn, CEO of Takeda Pharmaceuticals
Europe Limited.

IDM`s common stock will no longer trade on the NASDAQ Global Market. Detailed
instructions will be mailed to former IDM stockholders who did not tender their
shares in the tender offer that preceded the merger. These instructions will
outline the steps to be taken by such former IDM stockholders to obtain the same
US$2.64 per share as was paid in the tender offer. The price paid per share is
subject to any required tax withholding and no interest will be paid thereon.

About IDM Pharma, Inc.

IDM is focused on the development of innovative cancer products that either
destroy cancer cells by activating the immune system or prevent tumor recurrence
by triggering a specific adaptive immune response. IDM is dedicated to
maximizing the full therapeutic and commercial potential of its innovative
products to address the needs of patients and the physicians who treat these
patients. For more information about the company and its products, visit
www.idm-pharma.com.

About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda is a research-based global company with its main
focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one
of the global leaders of the industry, Takeda is committed to striving toward
better health for individuals and progress in medicine by developing superior
pharmaceutical products. Additional information about Takeda is available
through its corporate website, www.takeda.com.

Forward-Looking Statements

This press release includes forward-looking statements that are subject to risks
and uncertainties. All statements other than statements of historical fact are
statements that could be deemed forward-looking statements, including any
statements of the plans, strategies and objectives of management for future
operations; any statements of expectation or belief; and any statements of
assumptions underlying any of the foregoing. In addition, there are risks and
uncertainties related to Takeda`s ability to successfully incorporate IDM`s
assets into its business operations, the ability to complete post-approval
development commitments for MEPACT and the contribution of MEPACT to Takeda`s
European oncology franchise. These and other risks and uncertainties are
discussed in documents filed with the U.S. Securities and Exchange Commission by
IDM, the tender offer documents filed by Takeda or its affiliates and the
Solicitation/Recommendation Statement filed by IDM. All forward-looking
statements are based on information currently available to Takeda and IDM, and
neither Takeda nor IDM assumes any obligation to update any such forward-looking
statements or other statements included in this press release.

Takeda Pharmaceutical
In Japan:
Seizo Masuda, +81 3 3278 2037
masuda_seizo@takeda.co.jp
or
In Europe:
Richard Kenyon, +44 20 3116 8861
richard.kenyon@tpeu.co.uk
or
In the United States:
Manisha Pai, +1 617-551-7877
Manisha.Pai@mpi.com

Copyright Business Wire 2009